MCRI to build on CyGenics' stem cell scaffold
Friday, 13 August, 2004
Stem cell company CyGenics (ASX: CYN) will collaborate with the Murdoch Children's Research Institute to perform clinical trials demonstrating that stem cells expanded from umbilical cord blood using CyGenics subsidiary Cytomatrix's proprietary cell growth scaffold retain full functionality and effectiveness.
Cytomatrix will transfer the technology, which has been shown to work for the expansion of human bone marrow stem cells, cord blood stem cells and peripheral blood stem cells, to researchers working at the MCRI.
A grant of AUD$50,000 has been awarded to the company through the Federal Government's International Science Linkages Program to support the trials.
Lipid science receives new Australia-led online hub
The Lipid Network launched this month to build links between researchers, clinicians and industry...
Proposed Australian trial eyes up blood testing for Alzheimer's
Utilising networks of GPs across three states, a large-scale study intends on combining digital...
Applications open for $300K pandemic therapeutics fellowships
Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...
